Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 4/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 11/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14761953 | 0.85 | KDM4E (0.58) | PIK3CGRXFP1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL3570447 | 0.84 | RXFP1 (0.54) | PIK3CGRXFP1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL2302821 | 0.82 | RXFP1 (0.57) | PIK3CGRXFP1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL3578944 | 0.80 | RXFP1 (0.62) | PIK3CGRXFP1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL27772428 | 0.79 | RXFP1 (0.51) | PIK3CGRXFP1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL2300379 | 0.79 | RXFP1 (0.48) | PIK3CGRXFP1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL14762375 | 0.78 | RXFP1 (0.54) | RXFP1ALDH1A1KDM4EL3MBTL1NPSR1 | |
| SCHEMBL14762280 | 0.75 | RXFP1 (0.56) | RXFP1ALDH1A1KDM4EL3MBTL1NPSR1 | |
| SCHEMBL2302871 | 0.74 | RXFP1 (0.66) | PIK3CGRXFP1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL14762034 | 0.71 | RXFP1 (0.55) | RXFP1ALDH1A1KDM4EL3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-8614215-B2 | Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) | MERCK SERONO SA (CH) | 2013-12-24 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| EP-2118076-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | Merck Serono S.A. (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | PFKP, PDXK, PF4 | PIK3CG 595/4885RXFP1 1332/4885ALDH1A1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.